Market revenue in 2022 | USD 878.3 million |
Market revenue in 2030 | USD 1,541.3 million |
Growth rate | 7.3% (CAGR from 2022 to 2030) |
Largest segment | Estrogen and progesterone replacement therapy |
Fastest growing segment | Parathyroid Hormone replacement |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Estrogen and Progesterone Replacement Therapy, HGH replacement therapy, Thryoid hormone replacement therapy, Testosterone Replacement Therapy, Parathyroid Hormone replacement |
Key market players worldwide | Eli Lilly and Co, Bayer AG, Hisamitsu Pharmaceutical Co Inc, Pfizer Inc, Merck & Co Inc, Viatris Inc, Novo Nordisk A/S ADR, AbbVie Inc, Roche Holding AG ADR, Ascend Wellness Holdings Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hormone replacement therapy market will help companies and investors design strategic landscapes.
Estrogen and progesterone replacement therapy was the largest segment with a revenue share of 53.96% in 2022. Horizon Databook has segmented the France hormone replacement therapy market based on estrogen and progesterone replacement therapy, hgh replacement therapy, thryoid hormone replacement therapy, testosterone replacement therapy, parathyroid hormone replacement covering the revenue growth of each sub-segment from 2018 to 2030.
The pharmaceutical industry of France is progressing within an enormously competitive international environment and a strongly inventive & dynamic context. The availability of a well qualified/trained staff, high-quality research, and presence of an adaptable industry that is capable of fulfilling the changing market needs have made France a key player in the pharmaceutical space.
The French healthcare system is largely financed by government national health insurance, wherein 70.0% of the healthcare costs and 100.0% in case of costly or chronic conditions are reimbursed. The high prevalence of GHD in the country supports market growth.
There is an increase in preference for growth hormone replacement therapy and hormone therapy in France. The Safety and Appropriateness of Growth Hormone Treatments in Europe (SAGE) project helped determine efficacy of available treatment options.
Horizon Databook provides a detailed overview of country-level data and insights on the France hormone replacement therapy market , including forecasts for subscribers. This country databook contains high-level insights into France hormone replacement therapy market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account